Applied Clinical Trials: Observations from the Post-Approval Summit
We are moving to an age of active surveillance and this will create new issues, but also solutions,” said Richard Gliklich, MD, Harvard Medical School and president and chief executive officer of Outcome Sciences.
Read the full article »
BIO-IT World: CDER Stresses 'Active' Post-Approval Surveillance
Speakers at the recent Post-Approval Summit* left no doubt that we are entering a new era of active surveillance of post-approval drugs. Richard Gliklich, chairman of the conference, said a number of forces have recently changed the role of post-approval research from “what had been an afterthought to something far more intrinsic” to the delivery and evaluation of health products.
Read the full article »
BIO-IT World: McClellan Envisions Lifecycle Approach to Drug Surveillance
Rising drug development costs and public frustration about major drug recalls highlight the need for an active, post-market drug surveillance system, Mark McClellan told attendees at the recent Post-Approval Summit.
Read the full article »
SCRIP: Implications of the FDA’s increased focus on post-approval safety
The passage of the Food and Drug Administration Authorization Act (FDAAA) in September 2007 represents a sweeping overhaul of the US system for ensuring the safety of approved drugs.
Read the full article »
CWWeekly: CDER’s Woodcock Details Expanded Authority, Sentinel Concept at Post-Approval Summit
Opening the Post-Approval Summit at Harvard, keynote speaker Janet Woodcock, M.D., Director of the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), outlined her agency’s expanded authorities in the area of post-approval research oversight brought about by the passage of the FDA Amendments Act (FDAAA) into law at the end of March.
Read the full article »
ClinPage: FDA’s Woodcock On FDAAA
Last week, we quoted Wyeth’s Joseph Camardo on the renewed user fee legislation known as FDAAA. He’s not sure the new post-marketing environment is starkly different from the old one. In thinking of the still-murky FDAAA regulatory landscape, we were reminded of a lyric from The Who: “Meet the new boss, same as the old boss.”
Read the full article »
ClinPage: Wyeth on FDAAA
Because of the random sighting of Ira Spector at one conference or another, we’ve always had a soft spot for Wyeth. We don’t know Spector—no need to fret he has been consorting with the news media.
Read the full article »
ClinPage: Post-Approval? Or Pre-Apocalypse?
Maybe it’s the medical school ambiance. Or the end of a long Boston winter. But every year, for mysterious reasons, the Post Approval Summit feels a bit different than other meetings.
Read the full article »
CWWeekly: PDUFA Revitalization Act to Boost Post-Approval Sector
Congress' recent reauthorization of the U.S. Food and Drug Administration's (FDA) Prescription Drug User Fee Act (PDUFA) included a series of changes that will no doubt have profound effects on the clinical trials industry.
Read the full article (pdf) »
Postcast Interview: Dr. Nancy Dreyer Speaks to PharmaVoice on the Importance of Registries and the AHRQ Handbook
Listen
ClinPage: Post-Approval Summit Politician Serono Speak at Meeting
Mark Uehling, Editor, ClinPage
The Post-Approval Summit at Harvard, now in its third year, is the most cerebral conference on our calendar. It is also the meeting most larded with VIP speakers, including a preponderance of physicians who run a) large swaths of international companies or b) big slices of a regulatory bureaucracy in the U.S. or Europe.
Read the full article (pdf) »
CWWeekly: A CenterWatch Publication - May 2006
The recent, 2nd Annual Post-Approval Summit held at Harvard Medical School included two days of indepth sessions focusing on the evaluation of marketed treatments in real-world patient outcomes.
Read the full article (pdf) »
BIO-IT World: eCliniqua
Mark Uehling, Senior Science Editor
Last year, we recounted some of the Post Approval Summit's outstanding speeches by multiple FDA people, an ex-FDA boss and a dozen thought leaders from Pfizer, Genentech, and other companies. We thought it would be hard to top that meeting at the Harvard Medical School. We were wrong.
Read the full article (html) »
GCPJ: RiskMAPs - A Route to Drug Safety
Based on a presentation by Anne Trontell, MD, MPH, Deputy Director of the FDA's Office of Pharmacoepidemiology and Statistical Science
As the public calls for better tracking of adverse events and swifter action when a problem is identified the pharma industry must raise its game. Trontell discusses the FDA guidance designing a risk minimization action plan (RiskMAP). The article focuses on utility and design in three types of RiskMAPs: targeted education and outreach, patient reminder systems, and performance-linked access systems.
Read the full article (pdf) »
Get with the Guidelines for Cardiovascular Secondary Prevention
Kenneth LaBresh, MD, et al.
Research shows that Web-based quality initiatives demonstrably improve patient outcomes. Using a Web-based Patient Management Tool as part of a collaborative quality improvement initiative enhanced adherence to prevention guidelines in hospitalized patients with coronary artery disease.
Read the full article (pdf) »